Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 375,000 ordinary shares of 25 pence each.
- Purchase Price: 1,318.63 pence per share.
- Treasury Holdings: 105,128,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,840,302,811 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 375,000 shares on August 16, 2005, which were subsequently placed into Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 375,000 shares by the 1,318.63 pence price.
- Confirm the updated total share count (5,840,302,811 in issue) against subsequent filings to track dilution or further buybacks.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the authorized buyback program.